fludarabine has been researched along with Brill-Symmers Disease in 104 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (6.73) | 18.2507 |
| 2000's | 57 (54.81) | 29.6817 |
| 2010's | 39 (37.50) | 24.3611 |
| 2020's | 1 (0.96) | 2.80 |
| Authors | Studies |
|---|---|
| Bishton, MJ; Clifton-Hadley, L; Haynes, A; Lush, R; McMillan, A; Patmore, R; Rule, S; Turner, D; Wilson, W | 1 |
| Ansell, SM; Burnette, BL; Colgan, JP; Epperla, N; Habermann, TM; Inwards, DJ; Johnston, PB; Macon, WR; Markovic, SN; Micallef, IN; Nowakowski, GS; Pham, AQ; Porrata, LF; Ristow, KM; Wiseman, GA; Witzig, TE | 1 |
| Ahmed, S; Ahn, KW; Armand, P; Epperla, N; Fenske, TS; Hamadani, M; Jagasia, M; Jaglowski, S; Kenkre, VP; Savani, B; Shah, NN; Smith, SM; Sureda, A | 1 |
| Angelucci, E; Angrilli, F; Arcaini, L; Bertoldero, G; Cascavilla, N; Chiarenza, A; Dondi, A; Federico, M; Ferrari, A; Ferreri, AJM; Gaidano, G; Kovalchuk, S; Luminari, S; Manni, M; Marcheselli, L; Merli, F; Pulsoni, A; Rusconi, C; Salvi, F; Stelitano, C; Tarantino, V; Tucci, A; Vallisa, D; Vitolo, U | 1 |
| Angrilli, F; Arcaini, L; Brugiatelli, M; Carella, AM; Dell'olio, M; Di Raimondo, F; Dondi, A; Federico, M; Franco, V; Gaidano, G; Galimberti, S; Luminari, S; Marcheselli, L; Merli, F; Pulsoni, A; Rigacci, L; Sacchi, S; Stelitano, C; Tucci, A; Vitolo, U | 1 |
| Argnani, L; Broccoli, A; Casadei, B; Pellegrini, C; Pileri, S; Zinzani, PL | 1 |
| Cartron, G; Davies, A; Lei, G; Marcus, R; Morschhauser, F; Radford, J; Salles, G; Vitolo, U; Wassner-Fritsch, E; Wenger, M | 1 |
| Abbas, A; Barré, L; Dhilly, M; Dumontet, C; Fillesoye, F; Galateau, F; Gourand, F; Guillouet, S; Leporrier, M; MacKenzie, ET; Patin, D; Tirel, O | 1 |
| Alvarez De Celis, I; Baldini, L; Bari, A; Boccomini, C; Botto, B; Castellino, C; Chiappella, A; Chiarenza, A; Ciccone, G; De Angelis, F; De Renzo, A; Evangelista, A; Gamba, E; Ladetto, M; Lobetti-Bodoni, C; Parvis, G; Pinto, A; Rossi, G; Tucci, A; Vitolo, U; Zaja, F | 1 |
| Byrtek, M; Cerhan, JR; Dawson, K; Flowers, CR; Friedberg, JW; Link, BK; Martin, P; Ziemiecki, R | 1 |
| Campos, JG; Carrillo-Cruz, E; Cuadrado, IM; De la Cruz Vicente, F; Galiana, ML; Gonzalez, JF; Marín Niebla, A; Perez-Simón, JA; Rios-Herranz, E; Rodriguez, MS; Tocino, IE | 1 |
| Ali, S; Olszewski, AJ; Shafqat, H | 1 |
| Afrough, A; Hamdi, A; Hosing, CM; Lu, G; Muzzafar, T; Popat, UR; Qazilbash, MH | 1 |
| Hiroshima, Y; Ichikawa, N; Kirihara, T; Kobayashi, H; Kurihara, T; Mori, Y; Sato, K; Shibazaki, M; Sumi, M; Takeda, W; Ueki, T; Ueno, M | 1 |
| Cassaday, RD; Flowers, ME; Gopal, AK; Green, DJ; Guthrie, KA; Maloney, DG; Pagel, JM; Press, OW; Rajendran, JG; Rezvani, AR; Sandmaier, BM; Sorror, ML; Storb, RF; Storer, BE | 1 |
| Alvarez, I; Anastasia, A; Arcari, A; Bari, A; Botto, B; Carella, AM; Chiarenza, A; Dondi, A; Federico, M; Marcheselli, L; Puccini, B; Salvi, F | 1 |
| Li, H; Li, Z; Liu, H; Liu, W; Lü, R; Qiu, L; Xiong, W; Yi, S; Zou, D | 1 |
| Annechini, G; Argnani, L; Broccoli, A; Casadei, B; De Renzo, A; Gandolfi, L; Morigi, A; Pellegrini, C; Pulsoni, A; Quirini, F; Stefoni, V; Tonialini, L; Zinzani, PL | 1 |
| Bachanova, V; Devine, SM; Fenske, T; Gersten, I; Horowitz, M; Hosing, C; Laport, GG; Lazarus, HM; Logan, B; Longo, W; Nademanee, A; Riches, ML; Wu, J | 1 |
| Altés, A; Asensio, A; Besalduch, J; Briones, J; Campo, E; Colomer, D; Domingo-Domenech, E; Escoda, L; Estany, C; Fernández de Sevilla, A; Gardella, S; González-Barca, E; López-Guillermo, A; Magnano, L; Montoto, S; Moreno, C; Muntañola, A; Oriol, A; Pedro, C; Ribera, JM; Salar, A; Sancho, JM; Vivancos, P | 1 |
| Blazar, BR; Brunstein, CG; Burns, LJ; Cantero, S; Cao, Q; Majhail, N; McClune, B; McGlave, PB; Miller, JS; Tomblyn, M; Wagner, JE; Weisdorf, DJ | 1 |
| Angrilli, F; Baldini, L; Bari, A; Ilariucci, F; Lazzaro, A; Luminari, S; Marcheselli, L; Pozzi, S; Sacchi, S; Stelitano, C | 1 |
| Burgaleta, C; Cabrera, C; Canales, M; De la Serna, J; Fernández de Sevilla, A; Gonzalez, M; Martínez, R; Martínez-López, J; Montalbán, C; Monteagudo, MD; Paz-Carreira, J; Peñalver, FJ; Peñarrubia, MJ; Prieto, E; Queizán, JA; Rapado, I; Rivero, A; Salar, A; Sánchez-Godoy, P; Tomás, JF | 1 |
| Janikova, A; Koristek, Z; Kral, Z; Mayer, J; Navratil, M; Pavlik, T; Sticha, M; Vasova, I; Vinklarkova, J | 1 |
| Andreadis, C; Kanetsky, PA; Nasta, SD; Olin, RL; Schuster, SJ; Ten Have, TR | 1 |
| Disel, U; Karakoc, E; Paydas, S; Yavuz, S | 1 |
| Khouri, I; Tam, CS | 1 |
| Brice, P; Copin, MC; Fermé, C; Feugier, P; Lamy, T; Morschhauser, F; Mounier, N; Sebban, C; Solal-Celigny, P; Tilly, H | 1 |
| Giné, E; Gutiérrez-García, G; López-Guillermo, A | 1 |
| De Brasi, C; Narbaitz, M; Noriega, MF; Rodríguez, A; Slavutsky, I | 1 |
| Canales, M; de la Serna, J; de Oña, R; de Sevilla, AF; Martínez, R; Martínez-López, J; Montalbán, C; Paz-Carreira, J; Rapado, I; Rivero, A; Sánchez-Godoy, P; Tomás, JF | 1 |
| Jordheim, LP | 1 |
| Bredeson, C; Ewell, M; Goodman, SA; Horowitz, MM; Kahl, BS; Laport, GG; Negrin, RS; Tomblyn, MR; Vose, JM | 1 |
| Bajo, R; Burgaleta, C; Caballero, MD; Canales, M; De La Serna, J; De Oña, R; De Sevilla, AF; Díaz, N; Martínez, R; Martínez-López, J; Montalbán, C; Peñalver, J; Prieto, E; Queizán, JA; Salar, A; Sánchez-Godoy, P; Tomás, JF | 1 |
| Assisi, D; D'Andrea, M; Dessanti, L; Maini, CL; Petti, MC; Pisani, F; Sciuto, R | 1 |
| Freedman, AS; Sweetenham, JW | 1 |
| Argnani, L; Baccarani, M; Broccoli, A; Cavalieri, E; De Renzo, A; Derenzini, E; Fanti, S; Fina, M; Gandolfi, L; Montini, GC; Pellegrini, C; Pileri, S; Pulsoni, A; Quirini, F; Rossi, M; Scopinaro, F; Stefoni, V; Tani, M; Torelli, F; Zinzani, PL | 1 |
| Ai, WZ; Czerwinski, DD; Hsu, FJ; Hwang, J; Kohrt, HE; Levy, R; Taidi, B; Timmerman, J | 1 |
| Andresen, S; Bolwell, B; Copelan, E; Dean, R; Kalaycio, M; Pohlman, B; Rybicki, L; Sobecks, R; Sweetenham, J; Waterman, J | 1 |
| Khouri, IF | 1 |
| Bayer, R; Fung, HC; Gregory, SA; Karmali, R; Kassar, M; O'Brien, T; Shammo, JM; Venugopal, P | 1 |
| Argnani, L; Cabras, MG; Casadei, B; De Renzo, A; Derenzini, E; Fabbri, A; Gandolfi, L; Gobbi, M; Pellegrini, C; Perotti, A; Pulsoni, A; Rigacci, L; Voso, MT; Zaccaria, A; Zinzani, PL | 1 |
| Burgstaller, S; Drach, J; Einberger, C; Fridrik, M; Gaiger, A; Greil, R; Heintel, D; Hopfinger, G; Jäger, U; Mannhalter, C; Oberaigner, W; Porpaczy, E; Putman, M; Raderer, M; Skrabs, C; Zeitlinger, M | 1 |
| Kato, J; Kikuchi, T; Kohashi, S; Mori, T; Okamoto, S; Ono, Y; Shimizu, T; Yamane, A | 1 |
| McCormack, C; McCurdy, O; Prince, HM; Ritchie, D | 1 |
| Bard, V; Foon, KA; LaRocca, RV; Rohatgi, N; Sethuraman, G | 1 |
| Licht, A; Meier, R; Taverna, C; Trojan, A | 1 |
| Böck, HP; Forstpointner, R; Hänel, A; Hartmann, F; Hermann, S; Hiddemann, W; Metzner, B; Pott, C; Repp, R; Rothmann, F; Unterhalt, M; Wandt, H | 1 |
| Dreyling, M; Hiddemann, W; Unterhalt, M | 1 |
| Amir, G; Cohen, Y; Da'as, N; Libster, D; Polliack, A | 1 |
| Burrows, A; Edenfield, WJ; Ekstrand, J; Lucas, M; Myhand, RC; Nelson, DA; Waselenko, JK | 1 |
| Januszewicz, EH; Prince, HM; Seymour, JF; Tam, CS; Westerman, D; Wolf, MM | 1 |
| Böck, HP; Dreyling, M; Forstpointner, R; Hänel, A; Hartmann, F; Hermann, S; Hiddemann, W; Metzner, B; Pott, C; Repp, R; Rohrberg, R; Rothmann, F; Unterhalt, M; Wandt, H | 1 |
| Dreyling, M; Hiddemann, W; Lenz, G | 1 |
| Baumbach, T; Benner, A; Ho, AD; Kerowgan, M; Kraemer, A; Leo, A; Leo, E; Mey, U; Parwaresch, R; Scheuer, L; Schmidt-Wolf, IG; Schmitt, C | 1 |
| Aversa, S; Candela, M; Chisesi, T; Congiu, AM; Marino, G; Nati, S; Patti, C; Polacco, A; Porcellini, A; Ravetti, JL; Rizzoli, V; Rubagotti, A; Santini, G; Spriano, M; Vimercati, R; Zoli, V; Zupo, S | 1 |
| Asaka, M; Ehira, N; Fukushima, A; Imamura, M; Kanamori, H; Masauzi, N; Minami, H; Musashi, M; Obara, S; Ogura, N; Tanaka, J; Tsutsumi, Y; Yamato, H | 1 |
| Alam, A; Benyunes, M; Bernstein, SH; Bernstein, ZP; Blumenson, L; Brown, K; Chanan-Khan, A; Czuczman, MS; Donohue, K; Grillo-Lopez, A; Hernandez-Ilizaliturri, F; Klippenstein, D; Koryzna, A; Loud, P; McCarthy, P; Mohr, A; Rock, MK; Skipper, M; Stewart, C | 1 |
| Cabanillas, F; Coleman, M; Gregory, SA; Hagemeister, F; Zinzani, PL | 1 |
| Cesarman, E; Chadburn, A; Coleman, M; Fiore, J; Furman, RR; Goldsmith, SJ; Kostakoglu, L; Kroll, S; Leonard, JP; Muss, D; Niesvizky, R; Schuster, MW; Tidmarsh, G; Vallabhajosula, S | 1 |
| Byrd, JC; Diehl, LF; Flinn, IW; Garrett-Mayer, E; Goodman, SN; Grever, MR; Kasamon, YL; Lucas, MS | 1 |
| Avery, RK; Mawhorter, SD; Prayson, RA; Procop, GW; Sierk, A; Sobecks, R; Staugaitis, SM; Yen-Lieberman, B | 1 |
| Gale, R; Gray, A; Hancock, B; Hutchinson, J; Lloyd, A | 1 |
| Carney, D; Januszewicz, EH; Lin, KI; Prince, HM; Seymour, JF; Tam, CS; Westerman, D; Wolf, M | 1 |
| Mitra, S; Murphy, PT; O'Donghaile, D | 1 |
| Aly, F; Diehl, V; Rehwald, U; Schmitz, S; Steinmetz, T | 1 |
| Böck, HP; Dreyling, M; Einsele, H; Forstpointner, R; Hänel, A; Hartmann, F; Hiddemann, W; Lehmann, T; Metzner, B; Pott, C; Repp, R; Seymour, JF; Unterhalt, M; Wandt, H | 1 |
| Cabanillas, F; Hagemeister, FB; McLaughlin, P; Pro, B; Rodriguez, MA; Romaguera, J; Tiongson, LP; Younes, A | 1 |
| Anhalt, GJ; Cummins, DL; Meyerle, JH; Mimouni, D; Owens, N; Tzu, J | 1 |
| Forman, SJ; Kogut, N; Krishnan, A; Nademanee, A; Nakamura, R; Patane, K; Popplewell, L; Rodriguez, R; Ruel, N; Sarkodee-Adoo, C; Smith, E; Zain, J | 1 |
| Hartmann, JT; Kanz, L; Klingel, K; Kröber, SM; Meisinger, I; Weisel, K | 1 |
| Gadre, SA; Ge, Y; Lockhart, LH; Northup, JK; Velagaleti, GV | 1 |
| Brugiatelli, M; Federico, M; Liberati, M; Marcheselli, R; Merli, F; Orsucci, L; Pozzi, S; Sacchi, S; Tucci, A; Vallisa, D | 1 |
| Canales, MA; de Paz, R; Hernandez-Navarro, F; Martin-Salces, M | 1 |
| Altés, A; Asensio, A; Besalduch, J; Briones, J; Campo, E; Colomer, D; de Sevilla, AF; Domingo-Doménech, E; Escoda, L; Estany, C; Galán, P; Gardella, S; López-Guillermo, A; Montoto, S; Montserrat, E; Moreno, C; Oriol, A; Pedro, C; Ribera, JM; Vivancos, P | 1 |
| Chen, L; Lü, SQ; Ni, X; Song, XM; Wang, JM; Xu, XQ; Yang, JM; Zhang, WP | 1 |
| Bernardeschi, P; Del Conte, A; Dentico, P; Fiorentini, G; Giannessi, PG; Giustarini, G; Montenora, I; Rossi, S; Turrisi, G | 1 |
| Baccarani, M; Cabras, MG; De Luca, S; De Renzo, A; Derenzini, E; Fabbri, A; Fanti, S; Fattori, P; Fina, M; Gobbi, M; Guardigni, L; Marchi, E; Musuraca, G; Pellegrini, C; Perotti, A; Piccaluga, PP; Pileri, S; Pulsoni, A; Rigacci, L; Ronconi, S; Stefoni, V; Tani, M; Voso, MT; Zaccaria, A; Zinzani, PL | 1 |
| Alousi, A; Anderlini, P; Champlin, RE; Couriel, D; de Lima, M; Fayad, L; Giralt, S; Hagemeister, F; Hosing, C; Khouri, IF; Korbling, M; Kwak, LW; Lee, MS; McLaughlin, P; Medeiros, LJ; Neelapu, SS; Saliba, RM; Samaniego, F; Samuels, BI; Ueno, NT | 1 |
| Anolik, J; Conners, C; Fisher, RI; Friedberg, JW; Kleiner, A; Rich, L; Walker, AR | 1 |
| Lärfars, G; Samuelsson, J; Udén-Blohmé, AM | 1 |
| Hoskin, PJ; Kanegaonkar, R; Mahadevan, A | 1 |
| Catovsky, D; Killick, S; Matutes, E; Sternberg, AJ; Wotherspoon, AC | 1 |
| Azaceta, G; Gutierrez, M; Palomera, L; Soria, J; Varo, MJ | 1 |
| Emmanouilides, C; Kunkel, L; Rasti, S; Rosen, P; Territo, M | 1 |
| Peterson, BA | 1 |
| Belanger, C; Bouabdallah, R; Brice, P; Brousse, N; Coiffier, B; Haioun, C; Janvier, M; Neidhardt-Bérard, EM; Péaud, PY; Pico, JL; Solal-Celigny, P; Tilly, H | 1 |
| Battista, R; Bendandi, M; Cellini, C; Ciccone, F; De Renzo, A; Gentilini, P; Gherlinzoni, F; Gobbi, M; Guardigni, L; Lauta, VM; Magagnoli, M; Marra, R; Mazza, P; Moretti, L; Ricciuti, F; Ronconi, F; Stefoni, V; Tura, S; Zaccaria, A; Zinzani, PL | 1 |
| Horning, SJ | 1 |
| Chim, CS; Liang, R; Wong, SS; Yuen, KY | 1 |
| Crawley, CR; Foran, JM; Gupta, RK; Johnson, PW; Johnson, SA; Lister, TA; Matthews, J; Micallef, IN; Radford, JA; Rohatiner, AZ; Summers, K; Sweetenham, JW | 1 |
| Chee, YL; Culligan, DJ; Kurtz, JB; Molyneaux, P; Olson, JA; Watson, HG | 1 |
| Cabanillas, F; Dang, NH; Hagemeister, FB; Lee, MS; McAda, N; McLaughlin, P; Pate, O; Preti, AH; Rodriguez, MA; Romaguera, JE; Sarris, AH; Younes, A | 1 |
| Imrie, KR; Tinmouth, A; Zanke, B | 1 |
| Bassan, R; Di Gaetano, N; Erba, E; Golay, J; Introna, M; Rambaldi, A; Xiao, Y | 1 |
| Anderlini, P; Cabanillas, FF; Champlin, RE; Donato, ML; Gajewski, JL; Giralt, SA; Hagemeister, FB; Ippoliti, C; Khouri, IF; Korbling, M; Lee, MS; McLaughlin, P; Okoroji, GJ; Saliba, RM; Younes, A | 1 |
| Benyunes, M; Bernstein, SH; Bernstein, ZP; Brown, K; Czuczman, MS; Fallon, A; Grillo-López, AJ; Klippenstein, D; Loud, P; McCarthy, P; Miller, K; Mohr, A; Rock, MK; Skipper, M; Stewart, C; Wentling, D | 1 |
| Cabanillas, F; Ford, RJ; Jiang, Y; McLaughlin, P; Medeiros, LJ; Rassidakis, GZ; Sarris, AH; Thomaides, A; Tsimberidou, AM | 1 |
| Fezoui, H; Genet, P; Lionnet, F; Louvel, D; Pulik, M; Touahri, T | 1 |
| Jain, VK; Ogden, JL; Wilder, DD | 1 |
| Amir, G; Berrebi, A; Cohen, Y; Da'as, N; Libster, D; Polliack, A | 1 |
| Amir, G; Cohen, Y; Polliack, A | 1 |
| Diehl, V; Voliotis, D | 1 |
| Batlle, M; Feliu, E; Mate, JL; Millá, F; Ribera, JM; Rodríguez, L; Xicoy, B | 1 |
12 review(s) available for fludarabine and Brill-Symmers Disease
| Article | Year |
|---|---|
Determinants of the optimal first-line therapy for follicular lymphoma: a decision analysis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Decision Support Techniques; Disease Progression; Disease-Free Survival; Doxorubicin; Humans; Immunotherapy; Lymphoma, Follicular; Markov Chains; Prednisone; Quality-Adjusted Life Years; Rituximab; Vidarabine; Vincristine | 2010 |
Nonmyeloablative stem cell transplantation in follicular B-cell lymphoma.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Drug Resistance, Neoplasm; Graft vs Tumor Effect; Humans; Immunologic Factors; Immunotherapy; Lymphocyte Transfusion; Lymphoma, Follicular; Melphalan; Methotrexate; Middle Aged; Multicenter Studies as Topic; Rituximab; Stem Cell Transplantation; Tissue Donors; Transplantation Conditioning; Vidarabine | 2007 |
Current immunochemotherapy strategies in follicular lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Immunotherapy; Lymphoma, Follicular; Nitrogen Mustard Compounds; Prednisone; Radioimmunotherapy; Rituximab; Stem Cell Transplantation; Vidarabine; Vincristine | 2010 |
Allogeneic stem cell transplantation in follicular lymphoma.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Bone Marrow; Cyclophosphamide; Disease-Free Survival; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Lymphoma, Follicular; Mice; Myeloablative Agonists; Recurrence; Remission Induction; Risk Factors; Rituximab; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vidarabine | 2011 |
Rituximab plus chemotherapy in follicular and mantle cell lymphomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Mitoxantrone; Rituximab; Vidarabine | 2003 |
Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Survival Rate; Treatment Outcome; Vidarabine | 2004 |
The role of fludarabine in the treatment of follicular and mantle cell lymphoma.
Topics: Antineoplastic Agents; DNA (Cytosine-5-)-Methyltransferases; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Vidarabine | 2004 |
The role of mitoxantrone in the treatment of indolent lymphomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, Follicular; Middle Aged; Mitoxantrone; Neoplasm Staging; Randomized Controlled Trials as Topic; Remission Induction; Rituximab; Survival Analysis; Vidarabine | 2005 |
Current treatment of follicular low-grade lymphomas.
Topics: Antineoplastic Agents; Bone Marrow Transplantation; Hematopoietic Stem Cell Transplantation; Humans; Interferons; Lymphoma, Follicular; Vidarabine | 1999 |
Follicular lymphoma: have we made any progress?
Topics: Antineoplastic Agents; Combined Modality Therapy; Dose-Response Relationship, Drug; Female; Genetic Therapy; Hematopoietic Stem Cell Transplantation; Humans; Interferons; Lymphoma, Follicular; Male; Prognosis; Recurrence; Survival Rate; Vidarabine | 2000 |
Rituximab in combination with CHOP or fludarabine in low-grade lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Prednisone; Rituximab; Vidarabine; Vincristine | 2002 |
Challenges in treating hematologic malignancies.
Topics: Anemia; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Epoetin Alfa; Erythropoietin; Hematinics; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Prognosis; Quality of Life; Recombinant Proteins; Vidarabine | 2002 |
42 trial(s) available for fludarabine and Brill-Symmers Disease
| Article | Year |
|---|---|
The UK NCRI study of chlorambucil, mitoxantrone and dexamethasone (CMD) versus fludarabine, mitoxantrone and dexamethasone (FMD) for untreated advanced stage follicular lymphoma: molecular response strongly predicts prolonged overall survival.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Dexamethasone; Female; Follow-Up Studies; Genes, bcl-2; Humans; Kaplan-Meier Estimate; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Progression-Free Survival; Prospective Studies; Survival Rate; United Kingdom; Vidarabine; Young Adult | 2020 |
R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Neoplasm Staging; Prednisone; Prognosis; Prospective Studies; Survival Rate; Vidarabine; Vincristine | 2013 |
Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prednisone; Prognosis; Vidarabine; Vincristine | 2013 |
Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Lin
Topics: Age Factors; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Dexamethasone; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Rituximab; Vidarabine | 2013 |
Long-term outcomes of patients with persistent indolent B cell malignancies undergoing nonmyeloablative allogeneic transplantation.
Topics: Adult; Aged; Antibodies, Monoclonal; Antigens, CD20; Chronic Disease; Cohort Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Follicular; Male; Middle Aged; Myeloablative Agonists; Radioimmunotherapy; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Yttrium Radioisotopes | 2015 |
Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Lymphocyte Count; Lymphocytes; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Monocytes; Prednisone; Prospective Studies; Rituximab; Survival Rate; Vidarabine; Vincristine | 2015 |
Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Networ
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Middle Aged; Myeloablative Agonists; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2016 |
Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Survival Rate; Time Factors; Treatment Outcome; Vidarabine | 2017 |
Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation.
Topics: Adolescent; Adult; Aged; Child; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cyclosporine; Disease-Free Survival; Female; Humans; Immunosuppression Therapy; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mycophenolic Acid; Survival Analysis; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation; Young Adult | 2009 |
Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma.
Topics: Adult; Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Genes, bcl-2; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Prednisone; Remission Induction; Rituximab; Survival Analysis; Vidarabine; Vincristine | 2009 |
Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adult
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Recurrence; Rituximab; Tumor Burden; Vidarabine | 2010 |
Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Living Donors; Lymphoma, Follicular; Male; Methotrexate; Middle Aged; Remission Induction; Rituximab; Salvage Therapy; Siblings; Tacrolimus; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2011 |
Frontline treatment of follicular lymphoma with fludarabine, cyclophosphamide, and rituximab followed by rituximab maintenance: toxicities overcome its high antilymphoma effect. Results from a Spanish Cooperative Trial (LNHF-03).
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cooperative Behavior; Cyclophosphamide; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Neoadjuvant Therapy; Rituximab; Spain; Treatment Outcome; Vidarabine; Young Adult | 2011 |
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by ⁹⁰Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Induction Chemotherapy; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Prospective Studies; Radioimmunotherapy; Rituximab; Treatment Outcome; Vidarabine; Yttrium Radioisotopes | 2012 |
Prolonged disease-free survival and overall survival with CVP alternating with fludarabine in advanced follicular lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Humans; Immunotherapy, Active; Lymphoma, Follicular; Middle Aged; Prednisone; Treatment Outcome; Vidarabine; Vincristine; Young Adult | 2011 |
Fludarabine as a risk factor for poor stem cell harvest, treatment-related MDS and AML in follicular lymphoma patients after autologous hematopoietic cell transplantation.
Topics: Adult; Antineoplastic Agents; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukapheresis; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Male; Mitoxantrone; Myelodysplastic Syndromes; Neoplasms, Second Primary; Risk Factors; Time Factors; Transplantation, Autologous; Vidarabine | 2012 |
Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Radiopharmaceuticals; Rituximab; Survival Analysis; Vidarabine; Yttrium Radioisotopes | 2011 |
Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma).
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Lymphoma, Follicular; Mitoxantrone; Radioimmunotherapy; Vidarabine | 2012 |
Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Pilot Projects; Prognosis; Prospective Studies; Remission Induction; Rituximab; Sex Factors; Survival Rate; Tissue Distribution; Vidarabine | 2012 |
Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisolone; Remission Induction; Vidarabine; Vincristine | 2002 |
[Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Humans; Immunosuppressive Agents; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Retrospective Studies; Rituximab; Time Factors; Vidarabine | 2002 |
Rituximab plus chemotherapy in follicular and mantle cell lymphomas.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Mitoxantrone; Rituximab; Vidarabine | 2003 |
Post-transplant interleukin-2 in patients with low-grade lymphoid neoplasms previously treated with fludarabine is limited by hematologic toxicity.
Topics: Adult; Antigens, CD34; Cyclophosphamide; Female; Hematologic Diseases; Hematologic Neoplasms; Humans; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Neutrophils; Peripheral Blood Stem Cell Transplantation; Platelet Count; Prospective Studies; Recombinant Proteins; Remission Induction; Survival Rate; Vidarabine | 2003 |
The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Prospective Studies; Recurrence; Rituximab; Survival Analysis; Vidarabine | 2004 |
Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Recurrence; Rituximab; Vidarabine | 2004 |
Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Female; Flow Cytometry; Genes, bcl-2; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Rituximab; T-Lymphocyte Subsets; Vidarabine | 2005 |
Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Prospective Studies; Radioimmunotherapy; Treatment Outcome; Vidarabine | 2005 |
Phase I study of low-dose interleukin-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count; Cyclophosphamide; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Injections, Subcutaneous; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Longitudinal Studies; Lymphoma, Follicular; Male; Middle Aged; Vidarabine | 2005 |
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Female; Germany; Humans; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Mitoxantrone; Prospective Studies; Recurrence; Remission Induction; Rituximab; Salvage Therapy; Survival Rate; Vidarabine | 2006 |
Phase 2 study of fludarabine and paclitaxel in patients with recurrent low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome; Vidarabine | 2006 |
Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma.
Topics: Adult; Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Gene Rearrangement; Humans; Kaplan-Meier Estimate; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Polymerase Chain Reaction; Proto-Oncogene Proteins c-bcl-2; Rituximab; Thrombocytopenia; Time Factors; Treatment Outcome; Vidarabine | 2007 |
High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Recurrence; Survival Rate; Vidarabine | 2008 |
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Italy; Kaplan-Meier Estimate; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Neoplasm Staging; Probability; Radioimmunotherapy; Risk Assessment; Survival Analysis; Vidarabine; Yttrium Radioisotopes | 2008 |
Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; B-Lymphocytes; Combined Modality Therapy; Cyclophosphamide; Female; Follow-Up Studies; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Male; Middle Aged; Myeloablative Agonists; Prospective Studies; Recurrence; Remission Induction; Rituximab; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2008 |
Treatment of indolent lymphoma with fludarabine/mitoxantrone combination: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Vidarabine | 1998 |
Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d'Etudes des Lymphomes de l'Adulte.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Interferons; Lymphoma, Follicular; Male; Middle Aged; Multivariate Analysis; Prednisone; Prognosis; Survival Analysis; Teniposide; Vidarabine | 1999 |
Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Disease Progression; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Lymphocytic, Chronic, B-Cell; Linear Models; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Vidarabine | 2000 |
A phase II study to evaluate the combination of fludarabine, mitoxantrone and dexamethasone (FMD) in patients with follicular lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; DNA, Neoplasm; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Polymerase Chain Reaction; Recurrence; Treatment Outcome; Vidarabine | 2000 |
Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Genes, bcl-2; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Mitoxantrone; Neoplasm Staging; Neutropenia; Rituximab; Vidarabine | 2000 |
Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Immunotherapy, Adoptive; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Male; Methotrexate; Middle Aged; Platelet Transfusion; Recurrence; Remission Induction; Rituximab; Tacrolimus; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2001 |
Quantitative real-time polymerase chain reaction for monitoring minimal residual disease in patients with advanced indolent lymphomas treated with rituximab, fludarabine, mitoxantrone, and dexamethasone.
Topics: Actins; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 18; Dexamethasone; DNA; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Mitoxantrone; Neoplasm, Residual; Polymerase Chain Reaction; Rituximab; Translocation, Genetic; Vidarabine | 2002 |
Efficacy of fludarabine/mitoxantrone/dexamethasone alternating with CHOP in bulky follicular non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisolone; Probability; Prognosis; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Treatment Outcome; Tumor Burden; Vidarabine; Vincristine | 2002 |
51 other study(ies) available for fludarabine and Brill-Symmers Disease
| Article | Year |
|---|---|
Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Chemotherapy, Adjuvant; Databases, Factual; Female; Humans; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Radioimmunotherapy; Risk Factors; Rituximab; Vidarabine; Young Adult; Yttrium Radioisotopes | 2017 |
Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Calcineurin Inhibitors; Cyclophosphamide; Databases, Factual; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Male; Middle Aged; Rituximab; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2018 |
Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Follow-Up Studies; Humans; Lymphoma, Follicular; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisone; Rituximab; Vidarabine; Vincristine | 2018 |
Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Neoplasm Staging; Prognosis; Recurrence; Retrospective Studies; Rituximab; Survival Analysis; Vidarabine | 2013 |
2-[18F]fludarabine, a novel positron emission tomography (PET) tracer for imaging lymphoma: a micro-PET study in murine models.
Topics: Adult; Animals; Disease Models, Animal; Fluorodeoxyglucose F18; Humans; Lymphoma, Follicular; Mice; Mice, SCID; Positron-Emission Tomography; Radiometry; Tissue Distribution; Vidarabine | 2014 |
Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National LymphoCare Study.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Observational Studies as Topic; Prednisone; Prospective Studies; Rituximab; Treatment Outcome; United States; Vidarabine; Vincristine | 2013 |
Fludarabine, cyclophosphamide and rituximab as first-line treatment in patients with newly diagnosed follicular lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Lymphoma, Follicular; Male; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine | 2014 |
Disparate survival outcomes after front-line chemoimmunotherapy in older patients with follicular, nodal marginal zone and small lymphocytic lymphoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Febrile Neutropenia; Female; Humans; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Male; Outcome Assessment, Health Care; Prednisone; Rituximab; SEER Program; Survival Analysis; United States; Vidarabine; Vincristine | 2015 |
Donor cell-derived myelodysplastic syndrome with ring chromosome 7 after allogeneic hematopoietic stem cell transplant in 2 patients with lymphomas as primary disease.
Topics: Allografts; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Biomarkers, Tumor; Bone Marrow; Cell Transformation, Neoplastic; Chromosome Deletion; Chromosomes, Human, Pair 7; Cyclophosphamide; Disease Progression; ETS Translocation Variant 6 Protein; Female; Gene Deletion; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Living Donors; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Proto-Oncogene Proteins c-ets; Repressor Proteins; Ring Chromosomes; Rituximab; Transplantation Chimera; Vidarabine | 2014 |
[Therapy-related chronic myelogenous leukemia following RFM therapy in a patient with follicular lymphoma].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Follicular; Middle Aged; Mitoxantrone; Rituximab; Vidarabine | 2014 |
[Curative effect analysis of rituximab combined with intensive chemotherapy for follicular lymphoma patients with bone marrow involvement].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Humans; Lymphoma, Follicular; Middle Aged; Prednisone; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine; Vincristine; Young Adult | 2015 |
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Consolidation Chemotherapy; Female; Follow-Up Studies; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Positron-Emission Tomography; Remission Induction; Rituximab; Tomography, X-Ray Computed; Treatment Outcome; Vidarabine | 2016 |
Influence of MBL-2 mutations in the infection risk of patients with follicular lymphoma treated with rituximab, fludarabine, and cyclophosphamide.
Topics: Adult; Aged; Alleles; Anti-Infective Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Cyclophosphamide; Early Termination of Clinical Trials; Female; Gene Frequency; Genetic Predisposition to Disease; Genetic Variation; Haplotypes; Humans; Infections; Lymphoma, Follicular; Lymphopenia; Male; Mannose-Binding Lectin; Middle Aged; Multicenter Studies as Topic; Neutropenia; Prospective Studies; Risk; Rituximab; Spain; Vidarabine; Young Adult | 2009 |
Efficacious but insidious: a retrospective analysis of fludarabine-induced myelotoxicity using long-term culture-initiating cells in 100 follicular lymphoma patients.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Diseases; Colony-Forming Units Assay; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Female; Follow-Up Studies; Hematopoietic Stem Cells; Humans; Interferon-alpha; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Peripheral Blood Stem Cell Transplantation; Prednisone; Procarbazine; Retrospective Studies; Rituximab; Vidarabine; Vincristine | 2009 |
Severe pulmonary toxicity associated with fludarabine and possible contribution of rituximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Humans; Lung Diseases; Lymphoma, Follicular; Male; Middle Aged; Rituximab; Severity of Illness Index; Vidarabine | 2010 |
Biclonal follicular lymphoma: histological, clinical and molecular characteristics.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Chromosome Breakpoints; Clone Cells; Dexamethasone; Female; Gene Rearrangement; Genes, bcl-2; Humans; Lymphoma, Follicular; Mitoxantrone; Molecular Sequence Data; Neoplasm Staging; Polymerase Chain Reaction; Vidarabine | 2010 |
Relationship between deoxycytidine kinase (DCK) genotypic variants and fludarabine toxicity in patients with follicular lymphoma.
Topics: Alleles; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine Kinase; DNA Mutational Analysis; Drug-Related Side Effects and Adverse Reactions; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Gene Frequency; Genotype; Humans; Kaplan-Meier Estimate; Logistic Models; Lymphoma, Follicular; Lymphopenia; Neutropenia; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Vidarabine | 2011 |
Further evidences for pharmacogenetic assessment of nucleoside analogue-treated patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine Kinase; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Humans; Lymphoma, Follicular; Lymphopenia; Neutropenia; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Treatment Outcome; Vidarabine | 2011 |
FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by 90Yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Feasibility Studies; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Radioimmunotherapy; Retrospective Studies; Rituximab; Vidarabine; Yttrium Radioisotopes | 2011 |
Early initial therapy of advanced follicular lymphoma: the need for vigilance.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamide; Disease Progression; Follow-Up Studies; Humans; Lymphoma, Follicular; Neoadjuvant Therapy; Population Surveillance; Rituximab; Vidarabine | 2011 |
Long-term follow-up of reduced-intensity allogeneic hematopoietic stem cell transplantation for refractory or relapsed follicular lymphoma.
Topics: Adult; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Lymphoma, Follicular; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2012 |
Exacerbation of lymphomatoid papulosis during rituximab therapy.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Doxorubicin; Humans; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphomatoid Papulosis; Male; Middle Aged; Prednisolone; Rituximab; Vidarabine; Vincristine | 2014 |
Eosinophilic pneumonia after administration of fludarabine for the treatment of non-Hodgkin's lymphoma.
Topics: Antineoplastic Agents; Aortic Valve Stenosis; Female; Heart Failure; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Middle Aged; Pulmonary Eosinophilia; Vidarabine | 2002 |
Retreatment with rituximab alone induces sustained remission in a patient with follicular lymphoma with multiple extranodal sites of involvement, relapsing soon after primary treatment with fludarabine-rituximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Humans; Lymphoma, Follicular; Male; Middle Aged; Recurrence; Remission Induction; Rituximab; Vidarabine | 2003 |
Fludarabine, cyclophosphamide and mitoxantrone for untreated follicular lymphoma: a report from the non-Hodgkin's lymphoma co-operative study group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Disease-Free Survival; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm, Residual; Protein Transport; Proto-Oncogene Proteins c-bcl-2; Safety; Survival Rate; Treatment Outcome; Vidarabine | 2004 |
Successful treatment of lymphoma with fludarabine combined with rituximab after immune thrombocytopenia induced by fludarabine.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Humans; Lymphoma, Follicular; Male; Middle Aged; Rituximab; Thrombocytopenia; Treatment Outcome; Vidarabine | 2005 |
Fatal West Nile Virus infection after rituximab/fludarabine--induced remission for non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Fatal Outcome; Humans; Lymphoma, Follicular; Middle Aged; Remission Induction; Rituximab; Vidarabine; West Nile Fever; West Nile virus | 2005 |
Costs of chemotherapy for indolent follicular non-Hodgkin's lymphoma in the UK: an observational study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Costs and Cost Analysis; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Health Services; Humans; Lymphoma, Follicular; Male; Middle Aged; Prednisone; Retrospective Studies; United Kingdom; Vidarabine; Vincristine | 2006 |
Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Drug Synergism; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Remission Induction; Rituximab; Survival Rate; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2006 |
Another case of myelodysplasia with monosomy 7 following fludarabine-based chemotherapy.
Topics: Antineoplastic Agents; Chromosomes, Human, Pair 7; Female; Humans; Lymphoma, Follicular; Middle Aged; Monosomy; Myelodysplastic Syndromes; Vidarabine | 2006 |
Sensitivity analysis of cost factors for various therapy options in the treatment of follicular lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Computer Simulation; Cost-Benefit Analysis; Cyclophosphamide; Doxorubicin; European Union; Fees and Charges; Germany; Health Care Costs; Humans; Lymphoma, Follicular; Male; Models, Economic; Prednisone; Reproducibility of Results; Rituximab; Sensitivity and Specificity; Vidarabine; Vincristine | 2006 |
Lichenoid paraneoplastic pemphigus in the absence of detectable antibodies.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; B-Lymphocytes; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Esophageal Diseases; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunity, Cellular; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Lichenoid Eruptions; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mucositis; Paraneoplastic Syndromes; Pemphigus; Prednisone; Recurrence; Rituximab; T-Lymphocytes; Vidarabine; Vincristine | 2007 |
Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Busulfan; Cause of Death; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Graft vs Host Disease; Hepatic Veno-Occlusive Disease; Humans; Infections; Kaplan-Meier Estimate; Lung Diseases, Interstitial; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Proportional Hazards Models; Reoperation; Retrospective Studies; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2006 |
Progressive bicytopenia due to persistent parvovirus B19 infection after immunochemotherapy with fludarabine/cyclophosphamide and rituximab for relapsed B cell lymphoma.
Topics: Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Humans; Immunocompromised Host; Immunoglobulins, Intravenous; Immunotherapy; Leukopenia; Lymphoma, Follicular; Middle Aged; Parvoviridae Infections; Parvovirus B19, Human; Prednisolone; Recurrence; Rituximab; Vidarabine; Vincristine; Viremia | 2006 |
Do cytogenetic abnormalities precede morphologic abnormalities in a developing malignant condition?
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Burkitt Lymphoma; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 18; Chromosomes, Human, Pair 8; Chromosomes, Human, X; Clone Cells; Cyclophosphamide; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Genes, myc; Humans; Karyotyping; Lymph Nodes; Lymphoma, AIDS-Related; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Mutagenesis, Insertional; Pleural Effusion, Malignant; Prednisone; Rituximab; Translocation, Genetic; Trisomy; Vidarabine; Vincristine | 2007 |
Treatment-related acute myeloid leukemia with 11q23 translocation following treatment with fludarabine, cyclophosphamide and rituximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Middle Aged; Rituximab; Vidarabine | 2008 |
[A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Neoplasm Staging; Remission Induction; Survival Rate; Thrombocytopenia; Vidarabine | 2007 |
Fludarabine combination therapy for follicular lymphoma followed by acute myeloid leukemia: two further case records.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Fatal Outcome; Female; Humans; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Male; Middle Aged; Neoplasms, Second Primary; Vidarabine | 2008 |
Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma.
Topics: Adult; Agammaglobulinemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocyte Subsets; CD4 Lymphocyte Count; Cyclophosphamide; Female; Humans; Immunocompromised Host; Immunoglobulin Class Switching; Immunoglobulins, Intravenous; Immunologic Memory; Immunophenotyping; Lymphoma, Follicular; Rituximab; Sinusitis; Vidarabine | 2008 |
Fludarabine, as well as 2-chlorodeoxyadenosine, can induce eosinophilia during treatment of lymphoid malignancies.
Topics: Aged; Antineoplastic Agents; Cladribine; Eosinophilia; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphatic Diseases; Lymphoma, Follicular; Male; Middle Aged; Retrospective Studies; Vidarabine | 1996 |
Third space sequestration increases toxicity of fludarabine--a case report.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Drainage; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pleural Effusion; Sepsis; Vidarabine | 1997 |
Prolonged disease-free survival in relapsed/refractory low-grade lymphoma treated with fludarabine: a report of four cases.
Topics: Adult; Anthracyclines; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophosphamide; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Prednisone; Vidarabine; Vincristine | 1998 |
Fatal myelofibrosis following fludarabine administration in a patient with indolent lymphoma.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Fatal Outcome; Humans; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Pancytopenia; Prednisone; Primary Myelofibrosis; Vidarabine; Vincristine | 1998 |
Cryptococcal infection associated with fludarabine therapy.
Topics: Antineoplastic Agents; CD4-CD8 Ratio; Cryptococcosis; Fatal Outcome; Fungemia; Humans; Immunocompromised Host; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Vidarabine | 2000 |
Sight-threatening varicella zoster virus infection after fludarabine treatment.
Topics: Acyclovir; Aged; Aged, 80 and over; Antiviral Agents; DNA, Viral; Eye Infections, Viral; Female; Herpes Zoster; Herpesvirus 3, Human; Humans; Immunosuppressive Agents; Lymphoma, Follicular; Male; Middle Aged; Polymerase Chain Reaction; Retinal Necrosis Syndrome, Acute; Vidarabine; Waldenstrom Macroglobulinemia | 2000 |
Fludarabine in alkylator-resistant follicular non-Hodgkin's lymphoma.
Topics: Actuarial Analysis; Adult; Aged; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Follicular; Male; Middle Aged; Retrospective Studies; Survival Rate; Transplantation, Autologous; Treatment Outcome; Vidarabine | 2001 |
Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Blotting, Northern; Cisplatin; Complement System Proteins; Cytotoxicity Tests, Immunologic; Doxorubicin; Drug Synergism; Fluorescent Antibody Technique; Humans; Idarubicin; In Situ Nick-End Labeling; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Paclitaxel; Rituximab; Tumor Cells, Cultured; Vidarabine | 2001 |
Toxoplasmic encephalitis in a non-HIV patient with follicular lymphoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; CD4-Positive T-Lymphocytes; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Female; Humans; Immunocompromised Host; Interferon-alpha; Lymphoma, Follicular; Opportunistic Infections; Prednisone; Salvage Therapy; Teniposide; Toxoplasmosis, Cerebral; Vidarabine | 2002 |
Large-cell transformation of chronic lymphocytic leukemia and follicular lymphoma during or soon after treatment with fludarabine-rituximab-containing regimens: natural history- or therapy-related complication?
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Follow-Up Studies; Humans; Immunocompromised Host; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Neoplasms, Second Primary; Rituximab; Time Factors; Vidarabine | 2002 |
Development and rapid dissemination of Merkel-cell carcinomatosis following therapy with fludarabine and rituximab for relapsing follicular lymphoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Carcinoma, Merkel Cell; Humans; Lymphoma, Follicular; Male; Middle Aged; Neoplasms, Second Primary; Recurrence; Rituximab; Salvage Therapy; Vidarabine | 2002 |
Progressive multifocal leukoencephalopathy shortly after the diagnosis of follicular lymphoma in a patient treated with fludarabine.
Topics: Antineoplastic Agents; Humans; Immunosuppressive Agents; Leukoencephalopathy, Progressive Multifocal; Lymphoma, Follicular; Male; Middle Aged; Opportunistic Infections; Time Factors; Vidarabine | 2002 |